Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00168519 |
Recruitment Status :
Completed
First Posted : September 15, 2005
Last Update Posted : December 15, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diabetes Mellitus, Type 2 | Drug: nitroprusside, pentalong, imdur, AICAR, isoptin | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | Contraction Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes |
Study Start Date : | October 2002 |
Actual Study Completion Date : | April 2009 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1 |
Drug: nitroprusside, pentalong, imdur, AICAR, isoptin
Sodium Nitroprusside - one 30 minute intravenous infusion Pentalong - two tablets orally (total 160mg) Imdur - two tablets orally (total 120mg) |
- glucose metabolism [ Time Frame: 3 hours ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Patients with type 2 diabetes
- Non-smokers
- Free of overt coronary disease (stress ECG)
- Body mass index < 35 kg.m-2
- Fasting plasma glucose > 7 mmol.L-1 and / or post 75 gm oral glucose load plasma glucose levels of > 11.1 mmol.L-1
- Unmedicated (diet controlled)
Healthy controls
- Non-smokers
- Free of overt coronary disease (ECG)
- Body mass index < 30 kg.m-2
- Fasting plasma glucose < 6.1 mmol.L-1
- Unmedicated

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00168519
Australia, Victoria | |
Baker Heart Research Institute | |
Melbourne, Victoria, Australia, 8008 |
Principal Investigator: | Bronwyn A Kingwell, PhD | Baker Heart Research Institute |
ClinicalTrials.gov Identifier: | NCT00168519 |
Other Study ID Numbers: |
51/02 |
First Posted: | September 15, 2005 Key Record Dates |
Last Update Posted: | December 15, 2009 |
Last Verified: | December 2009 |
Diabetes Mellitus, Type 2 Blood Glucose Exercise |
Muscle Contraction Nitric Oxide Nitrates |
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Nitroprusside Antihypertensive Agents Vasodilator Agents Nitric Oxide Donors Molecular Mechanisms of Pharmacological Action |